Candida bloodstream infection (BSI) is associated with high mortality and morbitidy rates among critically ill patients 1, 2 . The incidence of candidemia varies from 24 to 32.3 episodes/per 10,000 admissions 1, 3, 4 , and the mortality rate was 22-60% [2] [3] [4] [5] [6] . Recent strategies of antifungal prophylaxis or preemptive therapy for selected high-risk patients account for emergence of fluconazole resistant strains and an increased prevalence of non-albicans Candida species 7-9 . The mortality rate of children with candidemia remains high 10, 11 , and most patients have severe medical illness, surgical risk factors, presence of artificial devices, and frequently exposed to some high-risk medications [12] [13] [14] . Numerous studies have described the epidemiology, clinical features, antifungal treatment and outcomes of children with candidemia 4, [10] [11] [12] [13] [14] [15] [16] . However, few researchers have investigated the reasons of treatment failure for children with candidemia [12] [13] [14] . The benefit of modifiable therapeutic strategies for candidemia is mainly derived from data and studies conducted in the adult settings [17] [18] [19] [20] . Studies of pediatric candidemia were often limited by small sample sizes 4, 14 , lack of antifungal susceptibility testing 4, 13, 16 , or did not analyze the impact of different treatment strategies on outcome 4, 15, 16 . The aims of this study were to describe the clinical characteristics of
Patients and Methods
Study population, setting, and design. We included all hospitalized patients with age ≤18 years old in Chang Gung Memorial Hospital (CGMH) from January 2003 through December 2015, for whom ≥1 blood culture were positive for Candida species and who had symptoms and signs compatible with candidemia. Demographic characteristics, predisposing factors within the preceding 30 days from the onset of Candida BSI (defined as the day of first positive blood culture for Candida species), clinical management, and 30-day follow-up period were recorded in a dedicated database. The study was approved by the Institutional Review Board and Human Research Ethics Committee of CGMH, and a waiver of informed consent for anonymous data collection was also approved.
Definitions. An incident episode of candidemia was defined as ≥1 positive blood culture drawn from a peripheral vein yielding a Candida isolate, with clinical symptoms and signs compatible with Candida BSI 2, 7, 16 . Episodes were considered to be separate if they occurred ≥1 month apart 21, 22 . Catheter-related Candida BSI was diagnosed when the catheter tip culture was positive for the same Candida species as those obtained from the peripheral vein and no evidence of infection at other site 18 . Severity of illness was measured by the Acute Physiology and Chronic Health Evaluation II (APACHE II) score on the day of candidemia and the presence of severe sepsis or septic shock at presentation 23 . The primary study outcome was clinical treatment failure, which was defined according to the Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria 24 as the following: (1) all-cause mortality between days 3 and 30 from the initial positive blood culture, or (2) persistent fungal BSI for ≥72 hours after the initiation of antifungal therapy. Patients who died within the first 72 hours were excluded from the analysis of outcome predictors to ensure that the potential impact of therapeutic strategies could be appropriately investigated. We also analyzed in-hospital all-cause mortality as secondary outcome.
Microbiological Studies. All Candida isolates were processed to have species re-identification using Matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF, Bruker Biotype, software version 3.0, USA) and molecular methodology by sequencing the internal transcribed spacer regions (ITS1 and ITS2) from ribosomal DNA. Therefore, the identities of Candida parapsilosis sensu stricto, Candida orthopsilosis and Candida metapsilosis isolates were confirmed. In vitro antifungal susceptibilities of isolates were evaluated according to the EUCAST-Antifungal Susceptibility Testing microdilution method 25, 26 Candida krusei* ATCC ® 6258 and Candida parapsilosis ATCC ® 22019 were used as the quality control strains for antifungal drug susceptibility testing.
Statistical Analysis. Categorical variables were compared using the χ 2 test or Fisher exact test, whereas student t test or Mann-Whitney U test were applied for continuous variables. All the significant tests were 2-tailed, with a P value less than 0.05 to be significant. We analyzed the impact of initial treatment strategy on the primary outcome with predictors for clinical failure assessed in the entire study population by using a backward stepwise logistic regression model.
For secondary outcome, the follow-up period was until death or discharge from hospital to evaluate variables related to death. A univariate logistic regression was fitted for each variable to test its relationship with mortality outcomes. Variables clinically relevant and statistically significant (P < 0.1) on univariate analysis were considered to build the multivariate regression model. Clinical interventions were maintained in the final model as a fixed variable. Potential confounders of treatment strategies (APACHE II score) were tested. Significant interactions between variables were ruled out. Statistical analyses were performed using SPSS, version 15.0 (IBM SPSS, Chicago, Illinois).
Results
A total of 335 episodes of candidemia were identified during the study group. Of these, 16 case-patients were excluded because the Candida spp was unidentified (n = 5), and missing data regarding hospital courses (n = 4) and final outcomes (n = 7). Hence, this report is based on 319 episodes of candidemia identified in 262 pediatric patients. At the time of candidemia, 106 episodes (33.2%) occurred in the neonatal intensive care unit (NICU), 124 (38.9%) in pediatric ICU (PICU), 13 (4.1%) in burn-surgical ICUs, and 75 (23.5) in pediatric wards. The median length of hospitalization before Candida BSI was 29.0 days (IQR, 15.0-53.0 days). Baseline characteristics of the study population are outlined in Table 1 .
Microbiological findings. There were three episodes where two different Candida species were obtained simultaneously on the same day and one episode where two different species were obtained on day 2 during the 30-day follow-up period. A bacterial pathogen was isolated in conjunction with Candida species in 31 episodes (9.7%) (the most common: gram-negative rods in 16, coagulase-negative staphylococci in 8, other gram-positive cocci in 13, and anaerobes in 2). Secondary candidemias were identified in a total of 48 (15.0%) episodes, with Candida isolates recovered from intra-abdominal space or abscess (n = 31), pleural fluid (n = 4), urinary source (n = 8), and cerebrospinal fluids (n = 5). Overall, 323 yeast strains were obtained from 262 episodes. Species distribution did not vary substantially between different ICU and general wards.
The results of in vitro susceptibility testing are summarized in C. glabrata (1 of 10), and no resistance among C. albican and C. tropicalis. However, the MIC 90 of echinocandins against C. parapsilosis and C. glabrata was higher than those recorded for the most common Candida species. All isolates were susceptible to amphotericin B.
Clinical Data and Candidemia Management. Severe sepsis and septic shock were the clinical presentation of candidemia in 127 (39.8%) and 89 (27.9%) episodes, respectively. After antifungal therapy, 61 (19.1%) had progressively deteriorated course and 14 cases had positive Candida strains recovered from more than two non-blood sterile sites. Four had an obstructing renal fungus ball and one had septic thrombophlebitis during the follow-up period. Blood cultures were persistently positive for more than 3 days in 42.0% (134 of 319).
Overall, 310 episodes (97.2%) were treated with specific antifungal agents for candidemia (Table 3) , including 45 (14.1%) episodes were breakthrough candidemia. All patients with candidemia were treated with standard dosing of antifungal agents. Antifungal therapy was initiated after a median of 2 days (range, 0-7) following the acquisition of the first diagnostic blood culture. The median duration of all antifungal therapy per episode was 17.0 days (range, 1-68). Of those 310 episodes for which an antifungal agent was used, 136 episodes (43.9%) had modification of the antifungal regimens during the treatment course. Nine cases never received targeted antifungal agents, and all of them died before the Candida isolates were documented in the blood cultures.
As for CVC management, early CVC removal was performed within 48 hours and 72 hours after obtaining the first positive blood cultures in 26.8% (83 of 310) and 37.1% (115 of 310), respectively. Episodes with severe sepsis and septic shock were less likely to have early CVC removal (22.8% vs 44.8%, p < 0.001 and 22.5% vs 41.3%, p = 0.002, respectively). Elective CVC removal was done on 68 (21.3%) episodes, and 108 (34.8%) were treated with catheter in situ.
All cases of intra-abdominal candidiasis received surgical intervention. After effective antifungal therapy, 39.0% (121 of 310) had persistent fungemia for more than 72 hours. In total, 141 (45.4%) were considered as treatment failure based on our definition, and 22 of them had candidemia resolved only after CVC removal.
Outcomes and Predictors of Mortality.
Cumulative mortality at 7 and 30 days after the onset of candidemia was 13.4% (35 of 262) and 25.2% (66 of 262), respectively. Overall, the candidemia-attributable mortality rate was 23.5% (75 of 319) and in-hospital mortality rate for pediatric patients with candidemia was 35.1% (92 of 262). The treatment strategies and outcomes did not change greatly during the study period, when cases were divided into three study period Candidemia caused by uncommon Candida spp. or non-albicans Candida spp. was associated with higher rate of treatment failure, so was delayed initiation of antifungal therapy (>48 hours) and underlying renal insufficiency (Table 4) We assessed predictors of candidemia-attributable mortality and final in-hospital mortality after episodes (cases) without antifungal treatment were excluded. Neonates had significantly higher of sepsis-attributable mortality and in-hospital mortality rates than children (32.1% vs 19.2%, P = 0.017 and 44.7% vs 29.8%, P = 0.022, respectively). On multivariate analysis (Table 5) , underlying hematological/oncological malignancy, delayed catheter removal, breakthrough candidemia and septic shock at onset were independently associated with fungemia attributable mortality. Independent risk factors for in-hospital mortality in children with fungemia were underlying renal insufficiency with/without hemodialysis (OR, 4.69; 95% CI: 1.60-13.75) and hematological/oncological malignancy (OR, 4.41; 95% CI: 1.64-11.90), delayed catheter removal (OR, 2.13; 95% CI: 1.01-4.52), and septic shock at onset (OR, 15.64; 95% CI: 7.08-34.55). The significantly independent factor of delayed catheter removal and septic shock did not change after analyzing the patient subgroup of non-neonatal children (Supplemental Table 1 ).
Discussion
There is relatively scarce information regarding the impact of specific therapeutic strategies on an adverse outcome of pediatric candidemia 6, 27, 28 , as the authors of recent cohort studies did not analyze the influence of illness severity, catheter removal and timing of antifungal treatments 11, 28 . Furthermore, these studies did not consider the effectiveness of antifungal agents based on in vitro antifungal susceptibility, and the second or recurrent episodes were often ignored 4, 10, 11, 28 . After multivariate analysis, we found early catheter removal, breakthrough candidemia, and septic shock at onset independently associated with treatment failure of candidemia in children.
The 30-day mortality of our cohort was slightly higher than previous pediatric studies 4, 14, 28 , which reported a mortality rate between 11.4% and 44% 4, 10, 11, 14, 27, 28 . The higher mortality rate in our patients with candidemia could be explained by the higher rates of severe sepsis and septic shock in our cohort. While septic shock has been found the independent risk factor of final mortality in the adult studies 6, 18, 29 , this issue was rarely mentioned in the pediatric population 4, 10, 11, 14, 27, 28 . Accordingly, septic shock at infection onset seems a clear surrogate marker for illness severity and emerged as independently associated with poor outcome in our cohort, since no universal illness scoring system can be applied simultaneously on both neonates and children.
The impact of CVC management on the outcome of candidemic patients have been extensively investigated 22, [30] [31] [32] [33] . While recent multicenter studies did not find significant impact of early CVC removal on outcome in either neonates or children 4, 11, 28 , we documented delayed CVC removal not only exerted a significant effect on the odds of clinical failure but also was associated with prolonged candidemia and final in-hospital mortality. However, whether prompt catheter removal contributes significantly to outcome remains a debatable issue because there are no randomized controlled trials, either in the adult or pediatric settings, to document the benefit when the source of candidemia is not the catheter. The conflicting conclusions of previous studies most likely resulted from different study designs and failure of controlling the bias of illness severity 11, 22, [29] [30] [31] [32] [33] , especially as there might also Table 3 . Therapeutic approaches according to patient age. *Within the first 72 hours of administration of systemic antifungal antifungal drugs, we excluded a total of 9 episodes who never treated with antifungal agents before the patient died. ¶ P values were the comparison between neonatal episodes and non-neonatal episodes.
be selection bias in their hospital. Nonetheless, based on our findings and the expert guidelines 34, 35 , we believe that CVC removal should be attempted in children with candidemia when feasible.
Several studies concluded echinocandin and anidulafungin treatments were associated with decreased treatment failure 30, 36, 37 , other studies had conflicting conclusions and found adequate source control and timely antifungal treatment were independently associated with greater risk of mortality 6, 11, 18, 29 . In our cohort, we found antifungal regimens did not have significant influence on treatment outcomes, which were significantly associated with early catheter removal, underlying comorbidities and severity of illness. In our cohort, very few patients received echinocandins as their initial treatment, which may be due to the fact that most Candida isolates of candidemia in children were susceptible to fluconazole or amphotericin B. Another possible cause of prolonged candidemia in patients who had retained catheter may be biofilm formation 38, 39 . In this situation, the recently published European guidelines recommend use of echinocandin or liposomal amphotericin B as the therapeutic regimen, which have in vitro activity against biofilms 40 . The presence of underlying chronic comorbidities and distributions of Candida species were supposed to affect the treatment outcomes 30, 41, 42 . In consistent with other studies in the pediatric population, our cohort did not include enough patients to support a worse outcome due to different Candida species 10, 11, 14, 28 . We found renal failure and hematological/oncological malignancy independently associated with final in-hospital mortality but not clinical treatment failure, which suggested these patients died of major organ failure after clearance of candidemia and could account for the high mortality rate of our cohort.
The proportion of fluconazole-resistant strains (14.0%) in our cohort was slightly higher than previous pediatric studies 11, 43 . However, antifungal resistance cannot explain the significantly higher rate of persistent fungemia after effective antifungal therapy 9, 18, 41 . Additionally, our cohort had higher rates of retained CVC when compared with other studies 18, 41 , which may be due to more patients had severe sepsis and septic shock and early CVC removal was not possible. Based on our results, prompt early catheter removal and aggressive treatment strategies in patients with septic shock would be critical to improve patient outcomes.
The issue of breakthrough candidemia was rarely mentioned in the pediatric studies, and previous reports concluded breakthrough candidemia mainly occurred in acutely ill patients, those with serious comorbid conditions, frequently neutropenic or previously treated with corticosteroids or other immunosuppressive drugs 22, [44] [45] [46] . In our cohort, breakthrough candidemia were mainly caused by non-albicans Candida species (73.3%), and in patients with neutropenia (44.4%), underlying hematological/oncological malignancy (24.4%) and under immunosuppressants (28.9%). In our cohort, most isolates of breakthrough candidemia were fluconazole susceptible, but it was found independently associated with treatment failure and mortality. Therefore, the higher treatment failure rate of breakthrough candidemia might be due to the severe underlying illness, and echinocandins are suggested 22 . There were some limitations in this study. This is a single center, retrospective study. Therefore, our observations may be less applicable to different institutions when compared with multicenter, prospective studies. We did not perform serial blood cultures follow-up systemically in every episodes, and the treatment strategies were not controlled by bias of illness severity. Furthermore, sample size limitations precluded any subgroup analysis according to the specific non-albicans Candida species as the pathogen.
In conclusion, we identified that delayed catheter removal, breakthrough candidemia and septic shock were the most important predictors of treatment failure. Underlying renal failure and hematological/oncological malignancy contribute significantly to candidemia-attributable mortality. The treatment outcomes did not improve over the past decade. Therefore, prompt early catheter removal and aggressive treatment strategies in patients with risk factors for adverse outcomes would be important.
Variables
Fungemia attributable mortality (total episodes = 310, mortality n = 66) Final in-hospital mortality* (total patients = 253, mortality n = 83) 
